Several large clinical studies, including KEYNOTE‐859 [24], CHECKMATE‐649 [25], and ORIENT‐16 [26], have evaluated the efficacy of chemotherapy combined with PD‐1/PD‐L1 inhibitors in patients with HER2‐negative advanced GC/GEJC. This evidence concerns the gene PDCD1 and gastric cancer.